Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
A Phase 3 Multi-Center, Randomized Controlled Evaluation of the Efficacy, Safety and Tolerability of Isunakinra in Subjects with Moderate to Severe Dry Eye Disease Poster #2874-A0083 Karen L. Tubridy, PharmD 1, Michael H. Goldstein, MD1,2, Marianne Magill1 Eleven Biotherapeutics, Cambridge, MA, United States, 2Ophthalmology, New England Eye Center/Tufts Medical Center, Boston, MA, United States. 1 ABSTRACT Purpose: Isunakinra (EBI-005) is a novel topical interleukin-1 receptor inhibitor optimized for topical treatment of ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC). The purpose of this Phase 3 study was to evaluate the efficacy, safety, and tolerability of isunakinra in subjects with moderate to severe dry eye. Results: Of the 669 subjects, 334 received vehicle-control and 335 received isunakinra; 92% completed the study. There were 33 drop outs in the isunakinra group and 20 in the vehicle control group. Baseline demographics of the two groups were similar. Isunakinra was generally safe and well tolerated in this study. No treatment related serious adverse events were reported. There was no statistically significant difference between the isunakinra treated group and the vehicle control group for the co-primary endpoints. Subjects in both the isunakinra and vehicle treatment groups showed statistically significant improvement from baseline on the co-primary endpoints as early as one week. Conclusions: In this study, isunakinra was generally safe and well tolerated and had a similar adverse event profile to vehicle and to earlier studies conducted with isunakinra. Isunakinra showed a statistically significant improvement compared to baseline for signs and symptoms of DED over the 12 week treatment period, however there was no statistically significant difference between the isunakinra and vehicle-control subjects for the study endpoints. 5 to 7 Days Prior to Day 1 Screening • • • • • • Week 6 Week 9 Week 12 Have a history of dry eye disease (DED) in both eyes for at least 6 months Subjects randomized • Subjects who completed study 314 (94) Reason for subject discontinuation At randomization (Visit 2): – Have a total OSDI score of ≥19 and <50 669 (100) 302 (90) Parameter Vehicle (N=334) Isunakinra (N=335) Age (years), Mean (SD) 60 (13.64) 60 (13.22) 274 (82%) 277 (83%) Female 616 (92) – Have complied with the 1-week run-in period No prior use of an IL-1 blocker 20 (6) 33 (10) 53 (8) Withdrawal by subject 8 (2) 16 (5) 24 (4) Adverse event 7 (2) 11 (3) 18 (3) Protocol violation – Have a total corneal fluorescein staining score of ≥5 (NEI scale) in the same qualifying eye as in Visit 1 and CFS <15 in at least one eye • 335 (100) Total N (%) Male – Continue to meet inclusion/exclusion criteria Objectives: • Co-Primary: CFS; pain or soreness by OSDI • Secondary: Total OSDI; CFS regions • Safety, tolerability, and immunogenicity 334 (100) Isunakinra N (%) Interleukin-1 (IL-1) is a key mediator of inflammation in many organ systems in animal and human studies (Dinarello 2001) and critical in ocular surface inflammation (Barbarino 2005; Chen 2010; Okanobo 2012; Zhu 2009; Bletsa 2009). • There was a statistically significant difference from baseline to week 12 within each treatment group for the co-primary endpoints of CFS and the OSDI pain question • Isunakinra was safe and well tolerated in this study and had a similar adverse event profile to prior studies in dry eye. 1 (0.3) 0 (0) 1 (0.1) Physician decision 0 (0) 1 (0.3) 1 (0.1) Lost to follow-up 4 (1) 3 (1) 7 (1) Other 0 (0) 2 (1) 60 (18%) 58 (17%) • The majority of patients improved from baseline while on treatment and were able to remain on treatment over the 12 weeks regardless of which treatment arm they participated in. 2 (0.3) White 271 (81%) 279 (83%) Black or African American 34 (10%) 30 (9%) Asian 17 (5%) 16 (5%) • We believe there may be an opportunity to look at longer term treatment with isunakinra to better understand how the disease severity changes and responds to treatment over time. In addition, we believe that looking at specific patient populations and different metrics will continue to be important in the treatment of dry eye because of the heterogeneity of the disease. Other 12 (4%) 10 (10%) OSDI painful or sore eye score, Mean (SD) 1.3 (0.8) 1.2 (0.8) Total OSDI score, Mean (SD) 35 (8.9) 35 (8.6) Total CFS (NEI score, study eye), Mean (SD) 8.6 (2.3) 8.5 (2.4) REFERENCES Barbarino S, Shen LL, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci 2005 46:2766-2771. Assessment of Genotyping Summary of Subjects with Treatment Emergent Adverse Events (TEAE) 92% of subjects completed the study • 96% overall compliance with study treatment Vehicle (N=334) Isunakinra showed no statistically significant difference from placebo in the co-primary endpoints of total CFS and the pain or sore eye question of the OSDI at Week 12 Any TEAE Severe TEAE There was a statistically significant difference (p<0.001) in the change from baseline to week 12 for the co-primary endpoints within treatment groups • Isunakinra (N=335) Ocular Non-ocular Ocular Non-ocular 58 (17%) 82 (25%) 68 (20) 77 (23%) 3 (1%) 5 (2%) 0 (0%) 5 (2%) Any study drug related TEAE 23 (7%) 11 (3%) 38 (11%) 7 (2%) Isunakinra was safe and well tolerated and the frequency of events was similar between the two treatment groups TEAE leading to study drug discontinuation 1 (0.3%) 1 (0.3%) 4 (1%) 0 (0%) • The most frequently reported ocular adverse event was eye irritation (4.5% placebo/4.5% isunakinra) TEAE leading to study termination 3 (1%) 3 (1%) 5 (2%) 1 (0.3%) • The most frequently reported non-ocular adverse event was pruritus (1.5% placebo/2.7% isunakinra) Any TESAE 0 (0%) 4 (1%) 0 (0%) 2 (0.6%) Any study drug related TESAE 0 (0%) 0 (0%) 0 (0%) 0 (0%) Outcome of death 0 (0%) • No difference was seen compared to vehicle-control in the co-primary endpoints of mean change from baseline at week 12 for total corneal fluorescein staining score (CFS, sign) or the OSDI pain question (symptom). Race CFS= Corneal Fluorescein Staining OSDI= Ocular Surface Disease Index • • • Gender Have ongoing DED, in the same eye or both eyes, as defined by the following criteria at screening (Visit 1): – A Total Corneal Fluorescein Staining Score of ≥6 (NEI scale) and <15 Off Treatment Baseline Demographics Vehicle N (%) – An OSDI score of ≥23 and ≤75 and have responded to the painful or sore eye question of the OSDI 21 Days Follow Up Week 15 FOLLOW UP Randomization 18 years of age and older that have given written voluntary consent Results Symptoms of DED are variable and include a dry eye sensation, foreign body sensation, irritation, burning, tearing, ocular pain, and itching among others. • • • 0 (0%) 0 (0%) • Bletsa A, Fristad I, Berggreen E. Sensory pulpal nerve fibres and trigeminal ganglion neurons express IL-1RI: A potential mechanism for development of inflammatory hyperalgesia. Int Endod J 2009; 42(11): 978-86. An exploration of genotyping was done to assess clinical relevance of IL-1 genotyping in ocular surface diseases. Chen YT, Nikulina K, Lazarev S, et al. Interluekin-1 as a Phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjögren’s Syndrome. Am J Pathol 2010 177:1333-1343. Interleukin Genetics (ILG) has developed a DNA based assay system to identify genetic haplotype pairs associated with the levels of IL-1β that are produced in response to certain stimuli. Haplotype pairs defined by SNPs in the IL-1 α and IL-1 β are grouped into predefined patterns that reflect IL-1 expression (Groups A, B, and C). Genotyping performed in CLIA certified laboratory at Interleukin Genetics, Inc. (Waltham, MA) using pre-defined proprietary patterns of IL-1 gene variations. There are distinct groupings that could be explored further based on these genoptype findings. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2001 117:3720-3732. International Dry Eye Workshop (DEWS) Report. Ocular surface 2007; 5: 65-204. Okanobo A, Chauhan S, Dastjerdi M, et al. Efficacy of topical blockade of Interleukin-1 in experimental dry eye disease. Am J Ophthalmol 2012; 154: 63-71. Zhu L, Shen J, Shang C, Park CY, Kohanim S, Yew M, Parker JS, Chuck RS. Inflammatory cytokine expression on the ocular surface in the botulism toxin B induced murine dry eye model. Molecular Vision 2009 15:250-258. ACKNOWLEDGMENTS Arkansas – Laurie Barber Arizona – Michael Depenbusch, Tariq Qamar California – John Bacharach, Damian Goldberg, Barry Katzman, Joseph Martel, Steven Rauchman, Kenneth Sall 0 (0%) Colorado – Lance Forstot Connecticut – Mark Milner Change from Baseline for Total CFS at each Visit (Standard Deviation) A Phase 2 study of isunakinra in moderate to severe dry eye subjects given 3x/day for 6 weeks demonstrated a benefit in the signs and symptoms of dry eye particularly those with a baseline OSDI<50. 0 1 3 6 9 12 Change from Baseline for OSDI Pain/Sore Eye at each Visit (Standard Deviation) 15 0 -2 -3 -4 -5 -6 1 3 6 9 12 Florida – Victor Perez Vehicle EBI-005 Time (Weeks) Differences between EBI-005 and vehicle were not statistically significant Study Endpoints Based on Genotype Category Ocular Treatment Emergent Adverse Events 15 Vehicle (N=334) EBI-005 (N=335) Subjects with at least one TEAE 58 (17.4%) 68 (20.3%) -0.6 Eye Irritation 15 (4.5%) 15 (4.5%) -0.8 Eye Pain 8 (2.4%) 9 (2.7%) Conjunctival Hyperemia 5 (1.5%) 9 (2.7%) Eyelid Itching 5 (1.5%) 9 (2.7%) 0 0 -1 Proposed MOA: EBI-005 BLOCKS IL-1αand IL-1β signaling on inflammatory, epithelial and nerve cells • EVALUATION VISITS • Isunakinra: Designed and Engineered to Block IL-1 • Subject Disposition STUDY RESULTS Dry eye is a common clinical problem affecting >7 million people (DEWS Report 2007). Elevated levels of IL-1 α and IL-1β drive ocular surface cellular signaling Week 3 Natural environmental study Double masked, vehicle controlled U.S. study, 650 subjects planned Inclusion criteria – CFS: Screen moderate-to-severe – OSDI: Screen moderate-to-severe • <50 at randomization Rescue tear use restricted CFS Change from Baseline • Week 1 RUN IN BACKGROUND • Vehicle Control — 3 times daily (~325 Subjects) Day 1 • 3 Week Follow Up Change from Baseline Pain Score of OSDI Methods: In this double-masked, vehicle-controlled study, 669 subjects at 46 sites in the USA with moderate to severe dry eye disease (DED) were randomized to topical isunakinra or vehicle control 1:1. Subjects were treated 3x/day for 12 weeks. Co-primary efficacy assessments were mean change from baseline at week 12 for total corneal fluorescein staining score (CFS, sign), and the OSDI pain question (symptom). Safety and tolerability of isunakinra were assessed. Subject Population – Key Eligibility Criteria Isunakinra 5 mg/ml — 3 times daily (~325 Subjects) 1 Week Run In CONCLUSIONS/KEY MESSAGES PATIENT DEMOGRAPHICS STUDY DESIGN -0.2 -0.4 -1 -1.2 -1.4 -1.6 Endpoint Total CFS Eye Pain Vehicle EBI-005 All other ocular AE’s below 2% Time (Weeks) Differences between EBI-005 and vehicle were not statistically significant Presentation #2874 /Poster #A0083, ARVO Annual Meeting, Session #: 310, Session Title: Dry Eye II. The poster presentation describes a Phase 3 efficacy trial of isunakinra in moderate to severe dry eye disease., Tuesday, May 3, 2016 08:30 AM to 10:15 AM OSDI Group N Vehicle CBL Isunakinra N CBL Georgia – Douglas Day Indiana – Kathleen Kelley, Clark Springs, Steve Wilson P-value Illinois – Lisa Wohl Kentucky – Paul Karpecki, John Meyer, Gregory Sulkowski ITT 334 -2.7 335 -2.4 0.237 A 47 -2.6 54 -2.4 0.691 Massachusetts – Jack Greiner, Jason Rothman B 28 -2.8 32 -3.6 0.325 Missouri – Gregg Berdy, Joseph Gira, Michael Korenfeld, Mujitaba Qazi, Joseph Tauber C 64 -3.3 46 -1.9 0.026 Nevada – Jack Abrams ITT 334 -0.5 335 -0.3 0.173 New York – Paul Hartman, Jodi Luchs, Kathryn Richdale A 47 -0.4 54 -0.5 0.495 North Carolina – Robert DaVanzo Maine – Jean Tibbetts Ohio – Marc Abrams B 28 -0.5 32 -0.4 0.739 C 64 -0.6 46 -0.4 0.337 South Dakota – Monte Dirks ITT 334 -7.9 335 -5.9 0.128 Tennessee – David Evans, A 47 -4.1 54 -4.7 0.855 Texas – William Lipsky, Robert Rice, Jay Rubin, Da-Thuy Van, Jeffrey Whisett B 28 -7.7 32 -8.0 0.929 Virginia – John Sheppard C 64 -10.5 46 -6.8 0.251 Presenting and corresponding author: Karen Tubridy, Pharm.D., Eleven Biotherapeutics Pennsylvania – Deepinder Dhaliwal, David Silbert, Daniel Zimmer